Research by Roberto suggests that PCSK9 inhibitors significantly improve lipid levels in male patients with familial hypercholesterolemia, thereby enhancing erectile function (Scicali et al., 2020). This evidence concerns the gene PCSK9 and familial hypercholesterolemia.